Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis (MG), the company announced Friday in its full-year 2022 financial report.
Featured Posts
Getting the balance right - Even as their clients are trying to make clinical trials more diverse and equitable, agencies are continuing their DE&I efforts to build a culture where diverse talent is welcomed.
Q&A: Considerations sponsors should make when implementing BYOD strategies in decentralized/hybrid trials - Besides reducing the burden of participation, sponsors benefit from lower costs and faster timelines. In addition, when patients are more engaged, patient protocol compliance increases.
Keytruda, could be on its way to snagging another indication as a first-line therapy for endometrial cancer after the company announced positive Phase III results Friday.
CanSino Biologics CEO Yu Xuefeng said on Friday he was confident his company’s experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech.
Gilead Sciences Inc. said on Friday the U.S. Food and Drug Administration had greenlighted expanded use of Trodelvy to treat the most common type of breast cancer, marking the third approval for the drug.
ReutersIndia will spend $79.6 million on strengthening its drug regulatory system, the health minister said on Friday, after the World Health Organization raised concerns about domestically produced cough syrups being linked to the death of 89 children in two countries.
Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, the company revealed Thursday in its 2022 full-year financial report.
Bristol Myers Squibb Co. on Thursday reported quarterly earnings that beat analysts’ estimates due to a smaller-than-expected drop in sales of cancer drug Revlimid, which is facing competition from cheaper generic rivals.
Eli Lilly and Co. missed Wall Street estimates for sales of its keenly-watched drug Mounjaro as well as older diabetes treatment, overshadowing a better-than-expected 2023 profit forecast.
Merck & Co. on Thursday forecast 2023 earnings below Wall Street estimates along with an expected steep decline in sales of its COVID-19 antiviral treatment, and its shares fell around 2%.
Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the pharmaceutical industry’s years-long pandemic boost is ebbing.
